Research Fraud “Fruitful” Area For Government Probes; AstraZeneca Brilinta Trial In Crosshairs
This article was originally published in The Pink Sheet Daily
HHS Office of Inspector General’s Mary Riordan advises drug makers to analyze their speaker programs and consulting arrangements for possible kickback activities.
You may also be interested in...
AstraZeneca played it straight when reporting a strong second quarter, outlining a robust late stage pipeline, a growing list of early assets and collaborations, while avoiding “the elephant in the room” - predator Pfizer’s paused-pursuit of the U.K. pharma.
AstraZeneca’s cardiovascular drug Brilinta – one of the group’s five key growth platforms - seems to have turned the corner to give a stellar performance in the second quarter – particularly in the crucial US market.
Sunshine Act penalties are relatively small but the payment disclosures could provide ammo and shortcuts for investigations into the more costly False Claims Act cases, U.S. attorneys say. On the flip side, disclosure may lead to better behavior.